Nautilus director receives 45,000 stock options

Nautilus Biotechnology, Inc. director Karen Akinsanya received a grant of stock options as part of her compensation.

Rhea-AI Filing Summary

Nautilus Biotechnology, Inc. director Karen Akinsanya received a grant of stock options as part of her compensation. The award covers 45,000 options to buy common stock at an exercise price of $2.28 per share, expiring on June 18, 2036.

These options vest in equal monthly installments over 12 months following the grant date, as long as she continues as a qualifying “Service Provider” under the company’s 2021 Equity Incentive Plan. After this grant, she holds 45,000 stock options directly.

Insider Trade Summary

Grant/Award: 45,000 shares

Grant/Award 1 txn

Insider Akinsanya Karen

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	45,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 45,000 contracts (Direct)

Footnotes (1)

1. F1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

Key Figures

Stock options granted: 45,000 options Exercise price: $2.28 per share Options expiration: June 18, 2036 +1 more

4 metrics

Stock options granted 45,000 options Grant to director Karen Akinsanya on June 18, 2026

Exercise price $2.28 per share Strike price for the 45,000 stock options

Options expiration June 18, 2036 Expiration date of granted stock options

Post-grant derivative holdings 45,000 options Total stock options held directly after this award

Key Terms

Stock Option (Right to Buy), 2021 Equity Incentive Plan, Service Provider, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

2021 Equity Incentive Plan financial

"defined in the the Issuer's 2021 Equity Incentive Plan"

Service Provider financial

"continuous status as a "Service Provider""

vesting financial

"shares subject to the Option shall vest on a monthly basis"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nautilus Biotechnology (NAUT) report for Karen Akinsanya?

Nautilus Biotechnology reported a grant of 45,000 stock options to director Karen Akinsanya. These derivative securities give her the right to buy common shares at a fixed price as part of her equity-based compensation package.

What is the exercise price of Karen Akinsanya’s new Nautilus (NAUT) stock options?

The stock options granted to Karen Akinsanya have an exercise price of $2.28 per share. This strike price is the amount she must pay per share if she chooses to exercise the options before they expire.

How many Nautilus (NAUT) stock options does Karen Akinsanya hold after this grant?

Following this transaction, Karen Akinsanya holds 45,000 stock options directly. The entire reported position in this filing comes from the new award, which is structured as a right to buy common stock at the stated exercise price.

When do Karen Akinsanya’s Nautilus (NAUT) stock options expire?

The granted stock options expire on June 18, 2036. She must exercise any vested portion before that expiration date; otherwise, the unexercised options will lapse and no longer provide the right to purchase Nautilus common shares.

How do the Nautilus (NAUT) stock options granted to Karen Akinsanya vest?

The 45,000 options vest in one-twelfth installments each month after the grant date. Vesting continues on the same calendar day each month, provided she maintains continuous status as a qualifying “Service Provider” under the 2021 Equity Incentive Plan.

Is Karen Akinsanya’s Nautilus (NAUT) stock option grant a cash transaction?

The grant itself involves no cash changing hands; it is an equity award. Any cash impact would occur only if she later exercises vested options by paying the $2.28 per-share exercise price to acquire Nautilus common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Akinsanya Karen

(Last) (First) (Middle)

C/O NAUTILUS BIOTECHNOLOGY, INC.

2701 EASTLAKE AVENUE EAST

(Street)

SEATTLE WASHINGTON 98102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nautilus Biotechnology, Inc. [ NAUT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.28	06/18/2026		A		45,000		(1)	06/18/2036	Common Stock	45,000	$0	45,000	D

Explanation of Responses:

1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

Remarks:

	/s/ Matthew B. Murphy, as Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)